<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683655</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-E301</org_study_id>
    <nct_id>NCT02683655</nct_id>
  </id_info>
  <brief_title>Study of Apatinib in Metastatic Esophageal Cancer</brief_title>
  <official_title>Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huai'an First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Huai'an First People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic&#xD;
      Esophageal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will receive apatinib treatment until disease progression or intolerable&#xD;
      toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>An expected average of 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib 500mg qd p.o.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib 750mg qd p.o.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg qd p.o.</description>
    <arm_group_label>Apatinib 500mg qd p.o.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 750mg qd p.o.</description>
    <arm_group_label>Apatinib 750mg qd p.o.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 to75 years old;&#xD;
&#xD;
          2. Pathologically diagnosed with metastatic esophageal squamous cell cancer with&#xD;
             measurable metastases outside the stomach (measuring ≥ 10mm on spiral CT scan,&#xD;
             satisfying the criteria in RECIST 1.1);&#xD;
&#xD;
          3. Failed in first-line chemotherapy or radiotherapy treatment;&#xD;
&#xD;
          4. ECOG PS of 0-1;&#xD;
&#xD;
          5. An expected survival of ≥ 3 months;&#xD;
&#xD;
          6. No treated by molecularly targeted therapy. If have received chemotherapy,&#xD;
             radiotherapy or surgery, must ≥4 weeks, and adverse reactions or wound has been&#xD;
             completely restored;&#xD;
&#xD;
          7. Major organ function has to meet the following criteria:&#xD;
&#xD;
             ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; ALB≥30g / L; TBIL≤1.5 times&#xD;
             the upper limit of normal (ULN); ALT and AST&lt;2 × ULN; Plasma Cr&lt;1.5 × ULN&#xD;
&#xD;
          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the&#xD;
             study;&#xD;
&#xD;
          9. Researchers believe that patients can benefit;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pts with other malignant tumor at the same time or in the past.&#xD;
&#xD;
          2. Pregnant or lactating women;&#xD;
&#xD;
          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt;150 mmHg&#xD;
             and diastolic blood pressure&gt;100 mm Hg) despite standard medical management; Coronary&#xD;
             heart disease greater than ClassII; Echocardiography: LVEF (LVEF)&lt;50%;&#xD;
&#xD;
          4. Factors that could have an effect on oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          5. Subjects with high gastrointestinal bleeding risk, including the following conditions:&#xD;
             local active ulcer lesions with positive fecal occult blood test (++); history of&#xD;
             black stool, or vomiting blood in the past 6 months;&#xD;
&#xD;
          6. Associated with CNS (central nervous system) metastases;&#xD;
&#xD;
          7. Abnormal Coagulation, with tendency of bleed;&#xD;
&#xD;
          8. With psychotropic drug abuse history and can't get rid of or mental disorder patients;&#xD;
&#xD;
          9. Anastomotic recurrence;&#xD;
&#xD;
         10. Participated in other clinical trials within 4 weeks;&#xD;
&#xD;
         11. Any other condition that might place the patient at undue risk or preclude a patient&#xD;
             from completing the study;&#xD;
&#xD;
         12. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen xiaofei, MD</last_name>
    <phone>+86-13915107001</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Huaian First People's Hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen xiaofei, MD</last_name>
      <phone>+86-13915107001</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

